⁴ The WOSCPS study population was not restricted to patients with diabetes. Based on the increased risk of cardiovascular events among patients with diabetes, the NNT for lipid-lowering therapy in a diabetic population is likely to be lower (better) than among a non-diabetic population.
[Return to Text]